Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma - A southwest oncology group study

David S Alberts, Nancy Mason-Liddil, Stephanie J. Green, John D. Cowan, William S. Fletcher, Barbara Neilan, Jerry T. Guy, Robert B. Epstein

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patients with a pathologically proven diagnosis of malignant melanoma were entered into a phase II trial of bisantrene. Eligibility criteria included: measurable, metastatic disease; performance status 0-2 SWOG; and adriamycin total cumulative dose of < 400 mg/m2. The initial bisantrene dosing schedule was 260 mg/m2 every three weeks for good risk patients. Due to the absence of an objective response and the lack of severe toxicity in the first 25 bisantrene treated patients, the starting dose was increased to 300 mg/m2 for good risk patients. Fifty-one patients received a median of two bisantrene courses (range 1-11 courses). Leukopenia was the major toxicity. Fifteen (68%) of the 22 good risk, intermediate dose patients (260 mg/m2), and 8 (80%) of the 10 good risk, high dose patients (300 mg/m2) evaluable for toxicity experienced mild-severe leukopenia. None of the 51 patients experienced a complete or partial response to bisantrene. Median survival was 3.3 months. We conclude that bisantrene is ineffective in the treatment of metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)289-292
Number of pages4
JournalInvestigational New Drugs
Volume5
Issue number3
DOIs
StatePublished - Sep 1987

Fingerprint

bisantrene
Melanoma
Leukopenia
Doxorubicin

Keywords

  • bisantrene
  • melanomas
  • phase II

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma - A southwest oncology group study. / Alberts, David S; Mason-Liddil, Nancy; Green, Stephanie J.; Cowan, John D.; Fletcher, William S.; Neilan, Barbara; Guy, Jerry T.; Epstein, Robert B.

In: Investigational New Drugs, Vol. 5, No. 3, 09.1987, p. 289-292.

Research output: Contribution to journalArticle

Alberts, DS, Mason-Liddil, N, Green, SJ, Cowan, JD, Fletcher, WS, Neilan, B, Guy, JT & Epstein, RB 1987, 'Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma - A southwest oncology group study', Investigational New Drugs, vol. 5, no. 3, pp. 289-292. https://doi.org/10.1007/BF00175300
Alberts, David S ; Mason-Liddil, Nancy ; Green, Stephanie J. ; Cowan, John D. ; Fletcher, William S. ; Neilan, Barbara ; Guy, Jerry T. ; Epstein, Robert B. / Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma - A southwest oncology group study. In: Investigational New Drugs. 1987 ; Vol. 5, No. 3. pp. 289-292.
@article{5a60aa384b654dddb15421bb908e57f2,
title = "Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma - A southwest oncology group study",
abstract = "Patients with a pathologically proven diagnosis of malignant melanoma were entered into a phase II trial of bisantrene. Eligibility criteria included: measurable, metastatic disease; performance status 0-2 SWOG; and adriamycin total cumulative dose of < 400 mg/m2. The initial bisantrene dosing schedule was 260 mg/m2 every three weeks for good risk patients. Due to the absence of an objective response and the lack of severe toxicity in the first 25 bisantrene treated patients, the starting dose was increased to 300 mg/m2 for good risk patients. Fifty-one patients received a median of two bisantrene courses (range 1-11 courses). Leukopenia was the major toxicity. Fifteen (68{\%}) of the 22 good risk, intermediate dose patients (260 mg/m2), and 8 (80{\%}) of the 10 good risk, high dose patients (300 mg/m2) evaluable for toxicity experienced mild-severe leukopenia. None of the 51 patients experienced a complete or partial response to bisantrene. Median survival was 3.3 months. We conclude that bisantrene is ineffective in the treatment of metastatic melanoma.",
keywords = "bisantrene, melanomas, phase II",
author = "Alberts, {David S} and Nancy Mason-Liddil and Green, {Stephanie J.} and Cowan, {John D.} and Fletcher, {William S.} and Barbara Neilan and Guy, {Jerry T.} and Epstein, {Robert B.}",
year = "1987",
month = "9",
doi = "10.1007/BF00175300",
language = "English (US)",
volume = "5",
pages = "289--292",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma - A southwest oncology group study

AU - Alberts, David S

AU - Mason-Liddil, Nancy

AU - Green, Stephanie J.

AU - Cowan, John D.

AU - Fletcher, William S.

AU - Neilan, Barbara

AU - Guy, Jerry T.

AU - Epstein, Robert B.

PY - 1987/9

Y1 - 1987/9

N2 - Patients with a pathologically proven diagnosis of malignant melanoma were entered into a phase II trial of bisantrene. Eligibility criteria included: measurable, metastatic disease; performance status 0-2 SWOG; and adriamycin total cumulative dose of < 400 mg/m2. The initial bisantrene dosing schedule was 260 mg/m2 every three weeks for good risk patients. Due to the absence of an objective response and the lack of severe toxicity in the first 25 bisantrene treated patients, the starting dose was increased to 300 mg/m2 for good risk patients. Fifty-one patients received a median of two bisantrene courses (range 1-11 courses). Leukopenia was the major toxicity. Fifteen (68%) of the 22 good risk, intermediate dose patients (260 mg/m2), and 8 (80%) of the 10 good risk, high dose patients (300 mg/m2) evaluable for toxicity experienced mild-severe leukopenia. None of the 51 patients experienced a complete or partial response to bisantrene. Median survival was 3.3 months. We conclude that bisantrene is ineffective in the treatment of metastatic melanoma.

AB - Patients with a pathologically proven diagnosis of malignant melanoma were entered into a phase II trial of bisantrene. Eligibility criteria included: measurable, metastatic disease; performance status 0-2 SWOG; and adriamycin total cumulative dose of < 400 mg/m2. The initial bisantrene dosing schedule was 260 mg/m2 every three weeks for good risk patients. Due to the absence of an objective response and the lack of severe toxicity in the first 25 bisantrene treated patients, the starting dose was increased to 300 mg/m2 for good risk patients. Fifty-one patients received a median of two bisantrene courses (range 1-11 courses). Leukopenia was the major toxicity. Fifteen (68%) of the 22 good risk, intermediate dose patients (260 mg/m2), and 8 (80%) of the 10 good risk, high dose patients (300 mg/m2) evaluable for toxicity experienced mild-severe leukopenia. None of the 51 patients experienced a complete or partial response to bisantrene. Median survival was 3.3 months. We conclude that bisantrene is ineffective in the treatment of metastatic melanoma.

KW - bisantrene

KW - melanomas

KW - phase II

UR - http://www.scopus.com/inward/record.url?scp=0023180266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023180266&partnerID=8YFLogxK

U2 - 10.1007/BF00175300

DO - 10.1007/BF00175300

M3 - Article

C2 - 3667164

AN - SCOPUS:0023180266

VL - 5

SP - 289

EP - 292

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -